Correction to “Alcohol-Induced Headache: A Narrative Review Based on Migraine Pathophysiology”

Article information

Headache Pain Res. 2026;.hpr.2025.0027.e1

Publication date (electronic) : 2026 August 19

doi : https://doi.org/10.62087/hpr.2025.0027.e1

Woo-Seok Ha

Department of Neurology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence: Woo-Seok Ha, M.D. Department of Neurology, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Republic of Korea Tel: +82-2-2228-1600, Fax: +82-2-393-0705, E-mail: haha88@yuhs.ac

This is a correction to an already published article (Headache Pain Res 2026;27(1):21-29; https://doi.org/10.62087/hpr.2025.0027).

The drug name was incorrectly spelled “imegepant” in two sentences under the subsection “2. Interface with migraine treatment and the potential role of calcitonin gene-related peptide-pathway–based therapies” in the section “CURRENT EVIDENCE AND THERAPEUTIC CONSIDERATIONS.” The correct spelling is “rimegepant.”

The corrected sentences are provided below.

More recently, Lipton and colleagues introduced the concept of “situational prevention,” in which rimegepant is used for prophylactic purposes during periods with increased risk of migraine attacks.

While rimegepant has demonstrated minimal hepatotoxicity with short-term use, its safety profile when administered in the context of recent alcohol consumption, including repeated or situational use, remains insufficiently studied.

We apologize for any inconvenience this error may have caused to readers.